SIDNEY BRAGINSKY - Corporate Board Profile

STRATA Skin Sciences, Inc.

Filing Date	Source Excerpt
2006-04-18	Sidney Braginsky has served as a member of our board of directors since 2001. He also currently serves as the Chairman and Chief Executive Officer of Digilab, LLC (a spectroscopy instruments manufacturer), Chairman of Atropos Technologies, LLC, a director of Double D Venture Fund, LLC, Noven Pharmaceuticals, Inc., Sword Diagnostics, Inc. and Micronix Pty Ltd. (an Australian medical device company), Chairman of the International Standards Organization U.S. Technical Advisory Group TC 172 on Optics and Photonics, Chairman of the Board of the City University of New York Robert Chambers Laboratory and Trustee on the Boards of Long Island High Tech Incubator and the Long Island Museum of Science and Technology. He formerly served as President of Olympus America and Mediscience Corp. and Chairman of Double D Venture Fund, LLC. Mr. Braginsky received his B.S. in biology from Queens College.
2007-04-20	Sidney Braginsky has served as a member of our Board of Directors since 2001. ... Mr. Braginsky's director compensation was $35,150 in 2006.
2008-04-15	Sidney Braginsky has served as a member of our Board of Directors since 2001. The compensation table shows he earned $32,300 in 2007.
2009-04-17	Sidney Braginsky has served as a member of our Board of Directors since 2001. He also currently serves as the Chairman and Chief Executive Officer of Digilab, LLC (a spectroscopy instruments manufacturer), Chairman of Atropos Technologies, LLC, a director of Diomed Inc., Double D Venture Fund, LLC, Noven Pharmaceuticals, Inc., Sword Diagnostics, Inc., DJO, Inc. (a Blackstone Group company), ESTECH (a private medical device manufacturing and distribution company), Invendo Medical GmbH (a German endoscopy developer), Geneva Acquisition Corporation and Micronix Pty Ltd. (an Australian medical device company), Chairman of the International Standards Organization U.S. Technical Advisory Group TC 172 on Optics and Photonics, Chairman of the Board of the City University of New York Robert Chambers Laboratory and Trustee on the boards of Long Island High Tech Incubator and the Long Island Museum of Science and Technology. He formerly served as President of Olympus America and Mediscience Corp. and Chairman of Double D Venture Fund, LLC.
2010-03-25	Sidney Braginsky has served as a member of our Board of Directors since 2001. The current members of our audit committee are Messrs. Braginsky, Cleary and Lufkin. The current members of our compensation committee are Messrs. Castleman, Braginsky and Chryssis. For 2009 our non-employee directors received an annual fee of $10,000 for serving as directors and an additional $500 per meeting for each full board or committee meeting attended. The chairman of each of our compensation committee, our audit committee and our nominating committee received an additional annual fee of $10,000. Also in December 2009, each of our non-employee directors received an annual stock option grant to purchase up to 7,500 shares of common stock. Such stock options will vest in full upon the first anniversary of issuance and have an exercise price equal to the closing price of our common stock on the date of the grant. Total compensation for Mr. Braginsky was $60,375.
2011-03-24	Sidney Braginsky has served as a member of our Board of Directors since 2001. For 2010 our non-employee directors received an annual fee of $15,000 for serving as directors and an additional $500 per meeting for each full board or committee meeting attended. In addition, the chairman of each of our compensation committee, our audit committee and our nominating committee received an additional annual fee of $10,000. Also in December 2010, each of our non-employee directors received an annual stock option grant to purchase up to 7,500 shares of common stock in respect of their service as directors for that year. Such stock options will vest in full upon the first anniversary of issuance and have an exercise price equal to the closing price of our common stock on the date of the grant.